TY - JOUR
T1 - The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis
T2 - A prospective survey of 202 cases in Japan
AU - Hidaka, Tomonori
AU - Shide, Kotaro
AU - Shimoda, Haruko
AU - Kameda, Takurou
AU - Toyama, Keiko
AU - Katayose, Keiko
AU - Kubuki, Youko
AU - Nagata, Kenji
AU - Takenaka, Katsuto
AU - Akashi, Koichi
AU - Okamura, Takashi
AU - Niho, Yoshiyuki
AU - Mizoguchi, Hideaki
AU - Omine, Mitsuhiro
AU - Ozawa, Keiya
AU - Harada, Mine
AU - Shimoda, Kazuya
PY - 2009/10
Y1 - 2009/10
N2 - Cytogenetic abnormalities were often observed in primary myelofibrosis patients. The presence of specific cytogenetic abnormalities, such as sole abnormalities of chromosome 13q-, 20q-, or -7/7q-, is reported to have the influence on the prognosis of primary myelofibrosis. We analyzed the data from the prospective survey of Japanese primary myelofibrosis patients which was conducted from 1999 to clarify the impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis. A total of 202 primary myelofibrosis patients had the cytogenetic and the prognostic data. Eighty (40%) out of 202 cases had cytogenetic abnormalities, and an association was evident for platelet counts. Although the presence of an abnormal karyotype did not affect the prognosis, primary myelofibrosis patients with cytogenetic abnormalities other than 13q- and 20q- showed an inferior prognosis compared to patients with a normal karyotype or sole 13q- or 20q- abnormalities. Patients with an unfavorable cytogenetic profile (abnormal cytogenetics other than 13q- or 20q-) also had a greater tendency to transform to leukemia than patients with a favorable cytogenetic profile (normal cytogenetics, sole abnormalities of either chromosome 13q-, or 20q-). Abnormal cytogenetics other than 13q- or 20q- in primary myelofibrosis patients has the poor prognostic effect for both survival and the risk of leukemic transformation.
AB - Cytogenetic abnormalities were often observed in primary myelofibrosis patients. The presence of specific cytogenetic abnormalities, such as sole abnormalities of chromosome 13q-, 20q-, or -7/7q-, is reported to have the influence on the prognosis of primary myelofibrosis. We analyzed the data from the prospective survey of Japanese primary myelofibrosis patients which was conducted from 1999 to clarify the impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis. A total of 202 primary myelofibrosis patients had the cytogenetic and the prognostic data. Eighty (40%) out of 202 cases had cytogenetic abnormalities, and an association was evident for platelet counts. Although the presence of an abnormal karyotype did not affect the prognosis, primary myelofibrosis patients with cytogenetic abnormalities other than 13q- and 20q- showed an inferior prognosis compared to patients with a normal karyotype or sole 13q- or 20q- abnormalities. Patients with an unfavorable cytogenetic profile (abnormal cytogenetics other than 13q- or 20q-) also had a greater tendency to transform to leukemia than patients with a favorable cytogenetic profile (normal cytogenetics, sole abnormalities of either chromosome 13q-, or 20q-). Abnormal cytogenetics other than 13q- or 20q- in primary myelofibrosis patients has the poor prognostic effect for both survival and the risk of leukemic transformation.
UR - http://www.scopus.com/inward/record.url?scp=70349158376&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70349158376&partnerID=8YFLogxK
U2 - 10.1111/j.1600-0609.2009.01298.x
DO - 10.1111/j.1600-0609.2009.01298.x
M3 - Article
C2 - 19549278
AN - SCOPUS:70349158376
SN - 0902-4441
VL - 83
SP - 328
EP - 333
JO - European Journal of Haematology
JF - European Journal of Haematology
IS - 4
ER -